CRIS (Curis Corp) קצב צמיחת רווח למניה בשנה הנוכחית
The annual net income per share trend for Curis, Inc. (CRIS) on GURU.Markets reflects the asset's volatility, with the latest reading at -30.40. Curis, Inc. (CRIS) management is focusing on the regulation of cellular pathways and partnerships with industry behemoths. Revenues are based on the commercialization of targeted therapies for leukemia and lymphomas. The absence of approved products eliminates inertial cash flow, leaving the budget dependent on equity issuances and external tranches.
פילוחי מדדים פיננסיים ומדדי שוק עבור Curis, Inc. (CRIS)
This indicator is calculated as the percentage deviation of current earnings per share from the value of the same period last year. The metric determines the growth rate of capital efficiency and the business's resilience to operational shocks. For Curis, Inc., which invests in oncology development and partnerships with pharma behemoths, this serves as a marker of the financial viability of the R&D cycle. By analyzing the volatility of annual earnings per share, an investor distinguishes real growth from speculation.
